These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 181495)

  • 1. Cyclic AMP-phosphodiesterase and epidermal mitosis.
    Birnbaum JE; Sapp TM; Tolman EL
    J Invest Dermatol; 1976 Aug; 67(2):235-9. PubMed ID: 181495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro.
    Rusin LJ; Duell EA; Voorhees JJ
    J Invest Dermatol; 1978 Aug; 71(2):154-6. PubMed ID: 210235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase inhibitors: their comparative effectiveness in vitro in various organs.
    Adachi K; Numano F
    Jpn J Pharmacol; 1977 Feb; 27(1):97-103. PubMed ID: 194077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences and similarities between guanosine 3',5'-cyclic monophosphate phosphodiesterase and adenosine 3',5'-cyclic monophosphate phosphodiesterase activities in neuroblastoma cells in culture.
    Prasad KN; Becker G; Tripathy K
    Proc Soc Exp Biol Med; 1975 Jul; 149(3):757-62. PubMed ID: 167381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
    Souness JE; Hassall GA; Parrott DP
    Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.
    Brackeen MF; Cowan DJ; Stafford JA; Schoenen FJ; Veal JM; Domanico PL; Rose D; Strickland AB; Verghese M; Feldman PL
    J Med Chem; 1995 Nov; 38(24):4848-54. PubMed ID: 7490734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physostigmine inhibition of 3',5'-cyclic AMP phosphodiesterase from cat sciatic nerve.
    Curley WH; Standaert FG; Dretchen KL
    J Pharmacol Exp Ther; 1984 Mar; 228(3):656-61. PubMed ID: 6323676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bovine luteal cyclic AMP and cyclic GMP phosphodiesterase activity; sensitivity to various drugs and hormones.
    Goff AK; Major PW
    FEBS Lett; 1976 Jan; 61(2):144-7. PubMed ID: 174943
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors.
    Glass WF; Moore JB
    Biochem Pharmacol; 1979 Apr; 28(7):1107-12. PubMed ID: 87197
    [No Abstract]   [Full Text] [Related]  

  • 10. Delayed stimulation of bone resorption in vitro by phosphodiesterase inhibitors requires the presence of adenylate cyclase stimulation.
    Ransjö M; Fredholm BB; Lerner UH
    Bone Miner; 1988 Jan; 3(3):225-34. PubMed ID: 2462948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds.
    de Cheffoy de Courcelles D; de Loore K; Freyne E; Janssen PA
    J Pharmacol Exp Ther; 1992 Oct; 263(1):6-14. PubMed ID: 1328613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes.
    Robicsek SA; Blanchard DK; Djeu JY; Krzanowski JJ; Szentivanyi A; Polson JB
    Biochem Pharmacol; 1991 Jul; 42(4):869-77. PubMed ID: 1651080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
    Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
    Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sodium butyrate in combination with prostaglandin E1 and inhibitors of cyclic nucleotide phosphodiesterase on human amelanotic melanoma cells in culture.
    Prasad KN; Sakamoto A
    Experientia; 1978 Dec; 34(12):1575-6. PubMed ID: 215447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inotropic responses to selective (RO 20-1724 and SQ 65,442) and nonselective (trequinsin) inhibitors of cyclic AMP-specific class IV phosphodiesterase in newborn, immature, and adult rabbit myocardium.
    Oquist NL; Strada SJ; Artman M
    Pediatr Res; 1992 Mar; 31(3):300-4. PubMed ID: 1313959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioprotection of mouse intestine by inhibitors of cyclic AMP phosphodiesterase.
    Lehnert S
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):825-33. PubMed ID: 91600
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition by reproterol of cAMP PDE in intact mastocytoma P-815 cells.
    Alvarez-Guerra M; Libertus H; Garay RP
    Pulm Pharmacol Ther; 2004; 17(4):213-8. PubMed ID: 15219266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes.
    Chan SC; Hanifin JM
    J Lab Clin Med; 1993 Jan; 121(1):44-51. PubMed ID: 8381148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible Contribution of Prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells.
    Banner KH; Hoult JR; Taylor MN; Landells LJ; Page CP
    Biochem Pharmacol; 1999 Nov; 58(9):1487-95. PubMed ID: 10513992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.